Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsAMMCF 35 EV-to-EBITDA is -3.90 as of Aug. 19, 2026. GuruFocus rates AMMCF with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 401 Biotechnology companies, Crism Therapeutics ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Crism Therapeutics's enterprise value is $9.80 Mil.
Crism Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.51 Mil. Therefore, Crism Therapeutics's EV-to-EBITDA for today is -3.90.
The historical rank and industry rank for Crism Therapeutics's EV-to-EBITDA or its related term are showing as below:
AMMCF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.38 Med: -2.56 Max: -1.26
Current: -3.88
During the past 13 years, the highest EV-to-EBITDA of Crism Therapeutics was -1.26. The lowest was -11.38. And the median was -2.56.
AMMCF's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.6
vs AMMCF: -3.88
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Crism Therapeutics's PE Ratio (TTM) for today is calculated as:
Crism Therapeutics's share price for today is $6.768.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Crism Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Crism Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMMCF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Crism Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's EV-to-EBITDA falls into.
Crism Therapeutics's current Enterprise Value is $9.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Crism Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crism Therapeutics (AMMCF) has a EV-to-EBITDA of -3.90 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Crism Therapeutics. According to the industry distribution chart, Crism Therapeutics ranks #999999 out of 401 companies in the Biotechnology industry.
Is Crism Therapeutics' EV-to-EBITDA too high?
Crism Therapeutics' current EV-to-EBITDA is -3.90. Based on the distribution chart, Crism Therapeutics ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crism Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #999999 out of 401 companies for EV-to-EBITDA. This places Crism Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.60, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Crism Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current EV-to-EBITDA is -3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (AMMCF) has a current EV-to-EBITDA of -3.90. The current EV-to-EBITDA is -3.90. Crism Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Crism Therapeutics (AMMCF), the current EV-to-EBITDA is -3.90 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
35GF Score
Get the complete analysis for AMMCF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMMCF has been successfully added to your 
